{"id":"irbesartan-amlodipine","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Peripheral edema"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hyperkalemia"}]},"_chembl":{"chemblId":"CHEMBL1200402","moleculeType":"Small molecule","molecularWeight":"567.06"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Irbesartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors on blood vessels and the heart, reducing vasoconstriction and aldosterone secretion. Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle cells, causing vasodilation. Together, these complementary mechanisms provide additive blood pressure reduction.","oneSentence":"This combination blocks angiotensin II receptors and calcium channels to reduce blood pressure through vasodilation and decreased vascular resistance.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:10.091Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":"Post-stroke Pneumonia","enrollment":13656},{"nctId":"NCT03476616","phase":"PHASE4","title":"Antihypertensive Pharmacological Therapy With Mineralocorticoid Receptor Antagonists in Obese Hypertensive Patients","status":"COMPLETED","sponsor":"Hippocration General Hospital","startDate":"2018-09-01","conditions":"Hypertension, Obesity","enrollment":198},{"nctId":"NCT06790927","phase":"NA","title":"Standardized Antihypertensive Treatment Protocol","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2025-02-24","conditions":"Hypertension","enrollment":400},{"nctId":"NCT06515678","phase":"","title":"Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Hospitalier Pitie-Salpetriere","startDate":"2024-05-20","conditions":"Ovarian Cancer, Antiangiogenic-Associated Hypertension, Adjuvant Bevacizumab","enrollment":9464},{"nctId":"NCT05663073","phase":"PHASE1","title":"Pharmacokinetics of Irbesartan/Amlodipine FDC and Co-administration of Irbesartan and Amlodipine in Healthy Volunteers","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2022-09-13","conditions":"Healthy Volunteers","enrollment":46},{"nctId":"NCT05475665","phase":"PHASE3","title":"Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2022-07-14","conditions":"Essential Hypertension","enrollment":157},{"nctId":"NCT05688098","phase":"PHASE1","title":"Pharmacokinetics of Irbesartan/Amlodipine High FDC and Co-administration of Irbesartan and Amlodipine High in Healthy Volunteers","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2022-09-23","conditions":"Healthy Volunteers","enrollment":44},{"nctId":"NCT05688085","phase":"PHASE1","title":"Pharmacokinetics of Irbesartan High/Amlodipine FDC and Co-administration of Irbesartan High and Amlodipine in Healthy Volunteers","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2022-10-18","conditions":"Healthy Volunteers","enrollment":44},{"nctId":"NCT05476354","phase":"PHASE3","title":"Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2022-07-05","conditions":"Essential Hypertension","enrollment":271},{"nctId":"NCT05377203","phase":"PHASE4","title":"Low-dose Quadruple Combination Therapy in Patients With Hypertension","status":"COMPLETED","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2022-07-13","conditions":"Hypertension, Arterial Hypertension","enrollment":90},{"nctId":"NCT04488978","phase":"PHASE2","title":"Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2020-05-21","conditions":"Essential Hypertension","enrollment":440},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT00535925","phase":"PHASE4","title":"Nephropathy In Type 2 Diabetes and Cardio-renal Events","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2005-10","conditions":"Diabetic Nephropathy","enrollment":850},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT00741585","phase":"PHASE4","title":"Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment","status":"COMPLETED","sponsor":"University of Vigo","startDate":"2008-09-01","conditions":"Essential Hypertension, Cardiovascular Disease, Stroke","enrollment":21983},{"nctId":"NCT02539810","phase":"PHASE4","title":"Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis (ANDORRA)","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-09","conditions":"Hypertension, Hypertension Resistant to Conventional Therapy, Angiographically Proven Grade III Unilateral or Bilateral Atherosclerotic Renal Artery Stenosis (ARAS) Greater Than or Equal to 60 Percent","enrollment":4},{"nctId":"NCT02148991","phase":"","title":"Clinical Trial in Patients With Hypertension and Left Ventricular Dysfunction","status":"COMPLETED","sponsor":"Elpen Pharmaceutical Co. Inc.","startDate":"2014-07","conditions":"Hypertension, Cardiac Arrhythmias, Diabetes Mellitus","enrollment":100},{"nctId":"NCT00219115","phase":"PHASE3","title":"A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-01","conditions":"Hypertension","enrollment":493},{"nctId":"NCT01500590","phase":"PHASE4","title":"Effect of Renin-angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria","status":"UNKNOWN","sponsor":"Hospital Authority, Hong Kong","startDate":"2011-11","conditions":"Diabetes, Hypertensive Disease","enrollment":1400},{"nctId":"NCT00987662","phase":"PHASE4","title":"Irbesartan Versus Amlodipine: The OBI Study","status":"WITHDRAWN","sponsor":"Aristotle University Of Thessaloniki","startDate":"2012-01","conditions":"Obesity, Hypertension","enrollment":""},{"nctId":"NCT01625494","phase":"PHASE3","title":"Study of Efficacy and Safety of Irbesartan/Amlodipine 4 Fixed Combination Therapy in Hypertensive Patients Uncontrolled on Irbesartan or Amlodipine Monotherapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-05","conditions":"Hypertension","enrollment":158},{"nctId":"NCT00224549","phase":"PHASE4","title":"PHARES Study: Management of Resistant Hypertension","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2005-04","conditions":"Hypertension","enrollment":180},{"nctId":"NCT00950066","phase":"PHASE2","title":"Irbesartan and Amlodipine Combination in Controlling Blood Pressure","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-07","conditions":"Hypertension","enrollment":270},{"nctId":"NCT00956644","phase":"PHASE3","title":"Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-07","conditions":"Hypertension","enrollment":406},{"nctId":"NCT00957554","phase":"PHASE3","title":"Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-07","conditions":"Hypertension","enrollment":435},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52},{"nctId":"NCT00264212","phase":"PHASE4","title":"AMISH : Aprovel for Management of Isolated Systolic Hypertension","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-08","conditions":"Hypertension","enrollment":436}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Irbesartan/Amlodipine","genericName":"Irbesartan/Amlodipine","companyName":"Handok Inc.","companyId":"handok-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination blocks angiotensin II receptors and calcium channels to reduce blood pressure through vasodilation and decreased vascular resistance. Used for Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}